AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire -- Raised $3.6 million in registered direct offering in second quarter - REHOVOT ...

ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 1570 in its research report dated August 19, 2025.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie announced an update on their ongoing clinical study. The pharmaceutical giant is conducting a Phase 1b clinical study ...

Trump calls for API stockpile, OCOchem to scale up chemicals from carbon dioxide, Covestro to buy isocyanates plants, and ...